Home » Stocks » Oncorus

Oncorus, Inc. (ONCR)

Stock Price: $15.51 USD 0.23 (1.51%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $15.54 +0.03 (0.19%) Oct 23, 5:38 PM

Stock Price Chart

Key Info

Market Cap 338.83M
Revenue (ttm) n/a
Net Income (ttm) -43.35M
Shares Out 21.78M
EPS (ttm) -1.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $15.51
Previous Close $15.28
Change ($) 0.23
Change (%) 1.51%
Day's Open 15.11
Day's Range 15.10 - 15.90
Day's Volume 21,674
52-Week Range 14.60 - 19.30

More Stats

Market Cap 338.83M
Enterprise Value 309.91M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 21.78M
Float 16.49M
EPS (basic) n/a
EPS (diluted) -1.99
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 12.25
Revenue n/a
Operating Income n/a
Net Income -43.35M
Free Cash Flow n/a
Net Cash 28.92M
Net Cash / Share 1.32
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-31.17-18.58
Net Income-30.70-18.05
Shares Outstanding11.309.59
Earnings Per Share-3.10-1.89
Operating Cash Flow-27.20-17.16
Capital Expenditures-0.98-0.29
Free Cash Flow-28.18-17.45
Cash & Equivalents45.2920.08
Net Cash / Debt45.2920.08
Book Value-74.30-40.08
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Oncorus, Inc.
Country United States
Employees 51
CEO Theodore T. Ashburn

Stock Information

Ticker Symbol ONCR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ONCR
IPO Date October 2, 2020


Oncorus, a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.